Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 1001-1007

  Huang, Zhao Hui ^a,b,c   Hua, Dong ^c   Du, Xiang ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Oxaliplatin; Polymorphism

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ARGININE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; ISOLEUCINE; OXALIPLATIN; PACLITAXEL; PROLINE;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CODON; CONTINUOUS INFUSION; ERCC1 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GSTP1 GENE; HUMAN; KAPLAN MEIER METHOD; LIGATION DETECTION REACTION METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; P53 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE FREE SURVIVAL; STOMACH CANCER; TREATMENT OUTCOME; XRCC1 GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CODON; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENES, P53; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 69049087667     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0956-2     Document Type: Article

References (30)

1. M Hejna S Wohrer M Schmidinger M Raderer 2006 Postoperative chemotherapy for gastric cancer Oncologist 11 136 145
2. S Sakuramoto M Sasako T Yamaguchi T Kinoshita M Fujii A Nashimoto H Furukawa T Nakajima Y Ohashi H Imamura M Higashino Y Yamamura A Kurita K Arai 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820
3. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997
4. DM Kweekel H Gelderblom HJ Guchelaar 2005 Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy Cancer Treat Rev 31 90 105
5. W Zhou S Gurubhagavatula G Liu S Park DS Neuberg JC Wain TJ Lynch L Su DC Christiani 2004 Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clin Cancer Res 10 4939 4943
6. J Viguier V Boige C Miquel M Pocard B Giraudeau JC Sabourin M Ducreux A Sarasin F Praz 2005 ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer Clin Cancer Res 11 6212 6217
7. H Kamikozuru H Kuramochi K Hayashi G Nakajima M Yamamoto 2008 ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy Int J Oncol 32 1091 1096
8. C Tibaldi E Giovannetti E Vasile V Mey AC Laan S Nannizzi R Di Marsico A Antonuzzo C Orlandini S Ricciardi M Del Tacca GJ Peters A Falcone R Danesi 2008 Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 14 1797 1803
9. E Martinez-Balibrea A Abad E Aranda J Sastre JL Manzano E Diaz-Rubio A Gomez-Espana J Aparicio T Garcia I Maestu A Martinez-Cardus A Gines E Guino 2008 Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer Eur J Cancer 44 1229 1237
10. B Liu J Wei Z Zou X Qian T Nakamura W Zhang Y Ding J Feng L Yu 2007 Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population Eur J Hum Genet 15 1049 1053
11. DM Townsend KD Tew 2003 The role of glutathione-S-transferase in anti-cancer drug resistance Oncogene 22 7369 7375
12. R Booton T Ward J Heighway L Ashcroft J Morris N Thatcher 2006 Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer J Thorac Oncol 1 679 683
13. E Goekkurt S Hoehn C Wolschke C Wittmer C Stueber DK Hossfeld J Stoehlmacher 2006 Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients Br J Cancer 94 281 286
14. WP Petros PJ Hopkins S Spruill G Broadwater JJ Vredenburgh OM Colvin WP Peters RB Jones J Hall JR Marks 2005 Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer J Clin Oncol 23 6117 6125
15. JF Kerr CM Winterford BV Harmon 1994 Apoptosis Its significance in cancer and cancer therapy. Cancer 73 2013 2026
16. P Dumont JI Leu AC Della Pietra 3rd DL George M Murphy 2003 The codon 72 polymorphic variants of p53 have markedly different apoptotic potential Nat Genet 33 357 365
17. Y Xu L Yao T Ouyang J Li T Wang Z Fan B Lin Y Lu Y Xie 2005 p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer Clin Cancer Res 11 7328 7333
18. T Toyama Z Zhang M Nishio M Hamaguchi N Kondo H Iwase H Iwata S Takahashi H Yamashita Y Fujii 2007 Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients Breast Cancer Res 9 R34
19. Huang ZH, Hua D, Li LH (2008) The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chemother Pharmacol (in press)
20. K Kawakami F Graziano G Watanabe A Ruzzo D Santini V Catalano R Bisonni F Arduini I Bearzi S Cascinu P Muretto G Perrone C Rabitti L Giustini G Tonini F Pizzagalli M Magnani 2005 Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy Clin Cancer Res 11 3778 3783
21. A Ruzzo F Graziano K Kawakami G Watanabe D Santini V Catalano R Bisonni E Canestrari R Ficarelli ET Menichetti D Mari E Testa R Silva B Vincenzi P Giordani S Cascinu L Giustini G Tonini M Magnani 2006 Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy J Clin Oncol 24 1883 1891
22. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ (2002) ERCC1 polymorphism is associated with differential ERCC1 gene expression. Proc Am Assoc Cancer 1591
23. R de las Penas M Sanchez-Ronco V Alberola M Taron C Camps R Garcia-Carbonero B Massuti C Queralt M Botia R Garcia-Gomez D Isla M Cobo M Santarpia F Cecere P Mendez JJ Sanchez R Rosell 2006 Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients Ann Oncol 17 668 675
24. B Keam SA Im SW Han HS Ham MA Kim DY Oh SH Lee JH Kim DW Kim TY Kim DS Heo WH Kim YJ Bang 2008 Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker BMC Cancer 8 148
25. J Stoehlmacher V Ghaderi S Iobal S Groshen D Tsao-Wei D Park HJ Lenz 2001 A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer Anticancer Res 21 3075 3079
26. A Ruzzo F Graziano F Loupakis E Rulli E Canestrari D Santini V Catalano R Ficarelli P Maltese R Bisonni G Masi G Schiavon P Giordani L Giustini A Falcone G Tonini R Silva R Mattioli I Floriani M Magnani 2007 Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy J Clin Oncol 25 1247 1254
27. G Yang XO Shu ZX Ruan QY Cai F Jin YT Gao W Zheng 2005 Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma Cancer 103 52 58
28. J Stoehlmacher DJ Park W Zhang D Yang S Groshen S Zahedy HJ Lenz 2004 A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 344 354
29. Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ (2008) Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer (in press)
30. J Stoehlmacher DJ Park W Zhang S Groshen DD Tsao-Wei MC Yu HJ Lenz 2002 Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J Natl Cancer Inst 94 936 942